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ABSTRACT
BACKGROUND AND OBJECTIVES: The use of drugs to 
treat renal failure has particularities due to pharmacokinetic 
changes present in such population. This study aimed at sup-
plying subsidies for a rational choice of analgesics to be used in 
patients with renal failure.
CONTENTS: Information is provided about pain prevalence 
and etiology in renal failure patients. In addition, the use of anti-
inflammatory drugs, opioid analgesics and adjuvant drugs for 
pain management is addressed.
CONCLUSION: Adjusting pharmacological therapy to renal 
function impairment may provide effective treatment with less 
adverse effects.
Keywords: Analgesics, Pain management, Renal failure.
RESUMO
JUSTIFICATIVA E OBJETIVOS: O uso de fármacos para o 
tratamento da dor em pacientes com insuficiência renal apresen-
ta particularidades devido às alterações farmacocinéticas presen-
tes nessa população. O objetivo deste estudo foi fornecer subsí-
dios para uma escolha racional dos analgésicos a serem utilizados 
em pacientes com função renal deficiente. 
CONTEÚDO: São fornecidas informações sobre prevalência 
e etiologia da dor em pacientes com insuficiência renal. Além 
disso, aborda-se a utilização de anti-inflamatórios, analgésicos 
opioides e fármacos adjuvantes para o tratamento da dor. 
CONCLUSÃO: O ajuste da terapêutica farmacológica ao com-
prometimento da função renal é capaz de prover um tratamento 
eficaz e com menos efeitos adversos.
Descritores: Analgésicos, Insuficiência renal, Manuseio da dor.
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INTRODUCTION
Chronic renal failure (CRF) is a common clinical condition 
followed by several associated diseases1. Due to increased sur-
vival with the advent of renal replacement therapy and renal 
transplantations, CRF patients are increasingly submitted 
to surgical procedures, with the need for effective analgesic 
therapy in the postoperative period. They are also submitted 
to several procedures inducing acute pain, such as frequent 
punctures for dialysis.
Moreover, CRF patients are subject to chronic painful syn-
dromes of different etiologies2. In addition to musculoskel-
etal and degenerative disorders, consequence or not of the 
kidney disease, this is a population with increased incidence 
of peripheral vascular ischemic disease and peripheral neu-
ropathies.
This study aimed at reviewing pain prevalence in patients 
with renal failure stressing etiologies, and at discussing as-
pects about drugs to its management.
RENAL FAILURE AND PAIN
In a study, authors have observed the prevalence of manifesta-
tions in patients chronically submitted to hemodialysis. Au-
thors have emphasized that musculoskeletal pain complaints 
were reported by 54% of patients of that study, something 
which so far had never been documented3. Cramps were ob-
served in 43%, headache in 19% and chest pain in 10%.
Pain epidemiological characteristics in chronic renal failure 
patients are poorly known. Most data are from studies on the 
quality of life or associated symptoms in patients chronically 
submitted to hemodialysis4-7.
In a population of chronic renal patients submitted to hemo-
dialysis, there were pain complaints of different etiologies2. 
Musculoskeletal pain was the most common cause. A small 
percentage has complained of pain induced by chronic dia-
lytic treatment, such as those triggered by cramps, headache 
and caused by fistula puncture. Musculoskeletal pain was ob-
served in 63.1% of patients, being osteoarthritis in 19.4%, 
undiagnosed pain in 18.4%, inflammatory arthritis in 6.8%, 
fracture in 9.7%, renal osteodystrophy in 4.9% and discitis/
osteomyelitis in 1.9%. Dialysis-induced pain was present in 
13.6% of patients, peripheral polyneuropathy in 12.6%, as-
sociated to peripheral vascular disease in 9.7% and carpal 
tunnel syndrome in 1.9%. Other causes of pain, correspond-
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ease, cancer and calciphylaxis. 
In a different study, authors have evaluated pain complaints 
of chronic renal patients admitted to nephrological units. 
Fifty three percent of patients have reported more than one 
cause for their pain8. Reasons were: surgical trauma (43.3%), 
peripheral vascular disease (32.1%), dialysis-related pain 
(26.4%), peripheral neuropathy (18.9%), osteoarthritis 
(9.4%), inflammatory arthritis (9.4%), cancer (9.4%), renal 
osteodystrophy (7.5%), gout (5.7%), calciphylaxis (3.8%), 
osteomyelitis (1.9%), osteoporotic fracture (1.9%) and poly-
cystic renal disease (1.9%).
Pain management is inadequate for a significant number of 
renal failure patients. Several factors may be pointed as re-
sponsible for such. Pain is not recognized as a major prob-
lem for chronic renal patients. In addition, pharmacokinetic 
changes and pharmacological interactions are very frequent in 
this population, making difficult or inhibiting management.
THERAPIES
Anti-inflammatory drugs, dipyrone and paracetamol
Anti-inflammatory drugs
Non-steroid anti-inflammatory drugs (NSAIDs) are used in 
the general population to treat mild to moderate pain. These 
agents block prostaglandins synthesis through the inhibition 
of cyclooxygenase enzymes (COX). COX type 1 (COX-1) is 
called constitutive, being expressed in most tissues; COX type 
2 (COX-2) is primarily induced, being mostly present in in-
flamed tissues9,10.
NSAIDs may increase the risk of bleeding in patients with 
uremia, for their synergistic effects on platelet aggregation in-
hibition11.
Renal prostaglandins synthesis inhibition is responsible for 
fluid retention, systemic hypertension and electrolytic disor-
ders observed with the use of NSAIDs. There is edema in 
3-5% of chronic anti-inflammatory users12. In hypertensive 
patients, it was observed increase of approximately 5mmHg 
in blood pressure13. Rennin release inhibition by renal prosta-
glandins, with less sodium supply to distal tubules is respon-
sible for hypercalcemia and other electrolytic disorders ob-
served with the use of NSAIDs. Hypercalcemia is pronounced 
especially in patients with uncompensated diabetes, heart 
failure, multiple myeloma, and users of angiotensin-convert-
ing enzyme, betablockers and potassium-sparing diuretics11.
NSAIDs also induce reversible decrease in glomerular filtra-
tion rate (GFR). Residual renal function in patients under 
renal replacement therapy is critical for the well-being of such 
patients. It is associated to longer survival, less weight gain 
between sessions and better solute clearance11.
Indomethacin is the NSAID decreasing GFR the most14. 
Naproxen, diclofenac, piroxicam and ibuprofen have inter-
mediate effect. Aspirin is the NSAID interfering the least with 
GFR15. Notwithstanding COX-2 induction being more often 
observed in inflammation sites, it is constitutively expressed 
in the kidney and has important function in the maintenance 
of renal hemodynamics. There is benefit with the use of se-
lective COX-2 inhibitors in patients with increased risk of 
hemorrhages. However, such drugs have renal effects similar 
to non-selective inhibitors, being contraindicated for renal 
failure patients11.
Dipyrone and paracetamol
These are drugs with analgesic and antipyretic action and lit-
tle or no anti-inflammatory activity. They have weak inhibi-
tory activity on COX-1 and COX-216,17.
Dipyrone action mechanism is still controversial. Experimen-
tal trials have shown inhibition of adenylate cyclase activation 
by hyperalgesic substances and direct blockade of calcium en-
trance in nociceptors18. Other authors have reported analgesic 
properties from the action of dipyrone metabolites on prosta-
glandins synthesis in the central nervous system (bulbus and 
periaqueductal gray matter)19.
Dipyrone has high clinical efficacy, low cost, broad availabil-
ity and safety margin, especially for renal patients9.
Antipyretic action mechanism proposed for paracetamol as-
sociates the drug to the inhibition of prostaglandins synthesis 
in the hypothalamus9. As analgesic, the drug has to be able to 
activate inhibitory serotoninergic antinociceptive pathways20.
Paracetamol is effective in doses up to 90mg.kg-1 or 4g.day-1. 
There is hepatotoxic activity when administered in high doses 
(150mg.kg-1, or 5-30g). Liver injury occurs by depletion of glu-
tathione stocks, leading to the building up of toxic metabolites 
in the hepatocyte, and to histopathological findings of centrol-
obular necrosis21. There are reports of kidney toxicity after ad-
ministration of glutathione to treat liver toxicity. Glutathione 
may provide the formation of nephrotoxic compounds which 
culminate with the activation of caspases and liposomal en-
zymes, starting apoptosis and renal dysfunction22.
Paracetamol is the analgesic of choice for elderly patients or 
those with impaired renal function23. In therapeutic doses, re-
nal toxicity is rare10. There is no need for dose adjustment in 
renal failure, but some authors recommend increasing dose in-
tervals from 6 to 8 hours when GFR is below 10 mL.min-1 24.
Opioid analgesics
Tramadol
This is a drug with agonist activity on opioid receptors (μ), 
and inhibitory action on serotonin and norepinephrine reup-
take, increasing such inhibitory neurotransmitters in the 
medullary synapse. It is metabolized in the liver, being 30% 
of the drug and 60% as active metabolites, excreted by the 
urine25. Although forming active metabolites, the risk of tox-
icity is low26.
Due to its action mechanisms, it is an effective drug to treat 
nociceptive and neuropathic pain, with the advantage of pro-
moting less sedation and ventilatory depression as compared to 
agonist opioids. Nausea is a common adverse effect. In patients 
under drugs decreasing convulsive threshold, such as selective 
serotonin reuptake inhibitor antidepressants, it may trigger 
epileptic crises, in addition to serotoninergic syndrome27.
In advanced CRF, elimination half-life may double, being 
necessary to decrease the dose - 200mg.day-1 if GFR is below 
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30mL.min-1, and 100mg.day-1 if GFR is below 10mL.min-1 25. 
It is dialyzable and safe for patients with dialytic CRF26. Since 
it is easily removed by hemodialysis, it should be adminis-
tered after the sessions28.
Codeine
This is a morphine derivative with moderate analgesic activ-
ity. Its liver metabolizing gives origin to codein-6-glucoronide 
(80%), and 5% is demethylated to morphine, which forms 
active metabolites which depend on renal excretion29,30. 
Analgesic activity of this drug comes from the action of its 
metabolites on μ opioid receptors30,31.
In patients with CRF, renal clearance of codeine and its me-
tabolites is significantly decreased, with higher risk of severe 
adverse effects, such as sedation, ventilatory depression and 
hypotension32. This way, care is needed when prescribing co-
deine to patients with renal failure31. Due to its high distribu-
tion volume and molecular weight, it is not easily removed 
by hemodialysis and should be avoided in patients needing 
renal replacement therapy31-33. Risk of toxicity is uncertain. It 
is dialyzable, but should be avoided, if possible, for patients 
with dialytic CRF26.
Oxicodone
This is a semi-synthetic opioid with twice the analgesic po-
tency of morphine. Its onset of action is one hour after oral 
administration and duration is 12h for the scheduled release 
formulation34.
It is metabolized in the liver and the drug depends on the 
kidney for the excretion of active metabolites and part of the 
original compound35. In the presence of renal failure there 
may be drugs build up and adverse effects as a consequence 
of the action of metabolites on the central nervous system31. 
Oxycodone should be avoided if GFL is below 60mL.min-1 34.
For being hydrosoluble, it is dialyzable. There are, however 
reports of lethargy and ventilatory depression in dialytic pa-
tients under multiple oxycodone doses per day36.
Toxicity risk is uncertain. It is not known whether it is dialyz-
able and whether it is safe for dialytic CRF patients26.
Morphine
This is the most widely studied opioid for renal failure. It is 
metabolized in the liver into morphine-3-glucoronide (M3G) 
and morphine-6-glucoronide (M6G), in addition to the for-
mation of diamorphine and normorphine. M6G is approxi-
mately 10 times more potent than its original compound. All 
metabolites and 10% of the original drug depend on renal 
excretion37.
There is M6G build up in renal failure, causing ventilatory 
and CNS depression. Since its blood-brain barrier crossing is 
slow, adverse effects of M6G may be long-lasting, persisting 
even after drug withdrawal or dialytic treatment, in spite of 
good drug and its metabolites clearance by dialysis38.
Analgesic and adverse effects of this drug are correlated to 
morphine and M6G plasma concentrations. This way, there is 
the need for decreasing the dose in 25%, 50% and 75% when 
there is CRF in stages 3, 4 and 5, respectively37. When safer 
opioids are available, morphine should be avoided in patients 
with renal failure39.
Recommended dose for patients with GFR above 50mL/min 
is 100%; for GFR 10-50mL/min it is 75% and for GFR be-
low 10mL/min it is 50%40.
Toxicity risk is uncertain. It is dialyzable, but should be 
avoided, if possible, for patients with dialytic CRF26.
Meperidine
This is a synthetic opioid with shorter duration analgesia as 
compared to remaining commonly used drugs. It has ap-
proximately 1/10 of morphine potency. Its active metabolite, 
normeperidine, has long elimination half-life (15-40h) and 
depends on renal excretion. There may be build up of this 
metabolite in renal failure patients with adverse effects such 
as shivering, myoclonus, seizure and delirium. So, it should 
not be used in patients with renal failure41. Remember that 
this opioid should not be used not only in patients with re-
nal failure, but also in those with normal renal function and 
acute or chronic pain. In addition to having no advantage 
over other opioids, it easily induces addiction. Toxicity risk 
is high. Meperidine is dialyzable, but it is unsafe for dialytic 
CRF patients26.
Fentanyl
This is a synthetic liposoluble opioid, approximately 80 times 
more potent than morphine. In addition to solution for 
intravenous or neuraxial use, it became popular due to its 
transdermal presentation, which reaches balance with plasma 
in approximately 12h after its application, with continuous 
release of the drug for 72h. It is adequate to treat pain in pa-
tients with stable opioid doses34.
Some countries have the oral transmucosal solution which 
provides fast absorption and is useful to treat incidental 
pain34.
Fentanyl is metabolized in the liver, with formation of inac-
tive metabolites31. It does not form active metabolites26. Since 
a minor percentage of the drug is excreted unaltered by the 
urine, this is a safe drug for renal failure patients42. Due to 
its high molecular weight, high protein binding, low hydro-
solubility and high distribution volume, the drug is not easily 
dialyzable43. It is not dialyzable but is safe for dialytic CRF 
patients26.
Recommended dose for patients with GFR above 50mL/min 
is 100%; for GFR between 10 and 50mL/min is 75% and for 
GFR below 10mL/min it is 50%40.
Methadone
This is a synthetic opioid 5-10 times more potent than mor-
phine. In addition to action on opioid receptors, it has antag-
onist effects on N-methyl-D-aspartate (NMDA) receptors34.
It is sold as racemic mixture where the isomer L-methadone 
acts on μ opioid receptors, while D-methadone acts on 
NMDA receptors. Due to its pharmacodynamics, it is useful 
to treat nociceptive and neuropathic pains44.
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In spite of its liposolubility, it has high bioavailability after 
oral administration. It is extensively bound to acid alpha-
1-glucoprotein, with broad tissue distribution, responsible 
for build up and long elimination half-life during chronic 
treatment with this opioid34.
It is metabolized in the liver and intestines, resulting in inac-
tive metabolites, being most part eliminated by the bile. It 
does not form active metabolites26. So, even not being cleared 
by hemodialysis, it is safe for renal failure patients45. How-
ever, there is the need for frequent evaluation with dose and 
interval adjustments because it is a long-lasting drug.
Recommended dose for patients with GFR above 50mL/min 
is 100%; for GFR between 10 and 50mL/min it is 100% and 
for GFR below 10mL/min it is 50-75%40. It is not dialyzable 
but is safe for dialytic CRF patients26.
ANTICONVULSANTS
Gabapentine
This is an anticonvulsant primarily used to treat neuropathic 
pain, with well tolerated adverse effects. It was synthesized as 
analog of gamma-aminobutyric acid (GABA), but does not 
significantly interact with this or other neurotransmitters. Its 
action mechanism is through the binding to alpha-2-delta 
subunits of voltage-dependent calcium channels, decreasing 
calcium entrance in nervous terminations and the release of 
excitatory neurotransmitters46.
It is excreted unaltered by the urine being the elimination de-
pendent on GFR. Approximately 35% of the drug are cleared 
during hemodialysis. This drug needs dose adjustment ac-
cording to GFR estimates when administered to patients with 
renal failure47.
If GFR is equal to or above 80mL/min-1 maximum daily dose 
may be 900 to 3600mg; if GFR 50 to 79, from 600 to 1800mg; 
if GFR between 30 and 49, 300-900mg; if GFR between 15 
and 29, 150 to 600mg and if GFR below 15, 150 to 300mg48.
Pregabalin
As gabapentin, pregabalin is a structural GABA analog with-
out GABAergic activity and acts on calcium channels alpha-
2-delta receptors. It is rapidly absorbed after oral administra-
tion, with bioavailability above 90%, and maximum plasma 
concentration reached one hour after its ingestion49.
It suffers little metabolism in humans (less than 2%), being 
excreted unaltered by the urine. So, it does not interact with 
liver enzymatic system, having little pharmacological inter-
action. However, there is the need for dose adjustment for 
patients with GFR below 60mL/min-1 50.
If GFR is equal to or above 60mL.min-1 maximum daily dose 
may be 600 mg; if GFR between 30 and 59, of 300mg; if GFR 
between 15 and 29, 150mg; and if GFR below 15, 75mg51.
Carbamazepine
This is an anticonvulsant with anticholinergic, antidepres-
sant, antiarrhythmic actions, in addition to inhibiting neu-
romuscular transmission. It induces increase of antidiuretic 
hormone release. Its action mechanism is through the inhi-
bition of sodium channels, suppressing spontaneous activity 
of A-delta and C fibers and decreasing glutamate release in 
nervous terminations46.
Used since the 1960s, it is still considered a first line drug to 
treat trigeminal neuralgia52. However, its clinical use requires 
attention, due to pharmacological interactions and adverse ef-
fects on the central nervous system53. It has high bioavailability 
after oral administration. There is 72% renal excretion, being 
3% unaltered. Since a small portion of the original compound 
is excreted by the urine, there will be no pharmacokinetic al-
teration in patients with impaired renal function46.
Oxcarbazepine
In spite of structural similarities with carbamazepine and of 
same clinical indications, oxcarbazepine has major pharma-
cokinetic differences46. As opposed to carbamazepine, it does 
not induce cytochrome P450, which significantly decreases 
its interaction with other substances54.
Its clinical effect is due to voltage-dependent sodium chan-
nels block, in addition to modulating calcium channels types 
N and P46.
There is 95% absorption of the dose by the gastrointestinal 
tract. Less than 1% of the dose is eliminated unaltered by the 
urine9. However, in patients with renal failure, dose should 
be cut in half, due to significant plasma level increase of its 
derivative mono-hydroxi, its primary metabolite54.
Similarly to carbamazepine, there is possibility, higher with 
oxcarbazepine, of dermatological reactions and hyponatremia 
during treatment with this anticonvulsant46.
ANTIDEPRESSANTS
Tricyclic antidepressants
Tricyclics are considered first line drugs to treat neuropathic 
pain55. Tertiary amines, such as amitriptyline, are potent nor-
epinephrine and serotonin reuptake inhibitors, whereas sec-
ondary amines, such as nortriptyline, act predominantly on 
norepinephrine reuptake56.
Amitriptyline bioavailability is low after oral administration. 
Its elimination is primarily renal, during several days, and the 
drug is not dialyzable due to its strong binding to plasma pro-
teins55. However, there is no need for dose adjustment in re-
nal failure57. Common amitriptyline adverse effects are poorly 
tolerated by renal failure patients. Among them, there are dry 
mouth, cardiac conduction abnormalities, weight gain, seda-
tion and orthostatic hypotension.
Nortriptyline is an active amitriptyline metabolite. It suffers 
extensive first liver passage effect, with formation of active 
metabolites. It causes less anticholinergic and cardiovascular 
effects than its original compound, being better tolerated55. 
There is no need for dose adjustment in renal failure57.
Venlafaxine forms an active metabolite (O-demethylvenlafax-
ine)58,59 and approximately 87% of the administered dose are 
excreted by the urine in the first 48h, being 5% as venla-
faxine, 26% as O-demethylvenlafaxine and 27% as inactive 
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metabolites. Its elimination half-life is similar to fluoxetine (3 
to 5 days), but in renal failure there is 50-180% increase60,61.
Duloxetine forms active metabolites which are mostly excret-
ed unaltered by the urine and in less quantity by feces62,63. 
Duloxetine should be avoided in patients with creatinine 
clearance below 30mL/min62.
CONCLUSION
The use of analgesics in patients with renal failure is a chal-
lenge. Adequate treatment should take into consideration pain 
intensity and duration and pharmacokinetic changes caused by 
renal disease. Matching drugs to patients’ clinical conditions 
may provide satisfactory analgesia with minor adverse effects 
and without deterioration of underlying clinical conditions.
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